Halozyme CEO exercises options, sells 50K shares
HALOZYME THERAPEUTICS, INC.
Rhea-AI Filing Summary
HALOZYME THERAPEUTICS, INC. CEO Helen Torley reported a series of option exercises and related share sales in May. Over May 11–13, she exercised options to acquire 50,000 shares of common stock at $12.07 per share and sold 50,000 shares in open-market trades at prices generally in the mid‑$60s to low‑$70s per share. The filing notes these transactions were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on March 21, 2025 and that the sales relate to options with a ten-year term expiring in February 2027. Following the reported transactions, she directly holds 767,780 shares of common stock and retains vested options to purchase 51,923 shares.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Exercise and Sale: 50,000 shares ($2.83M approx. pre-tax spread)
Exercise and Sale
18 txns
Insider
Torley Helen
Role
PRESIDENT AND CEO
Sold
50,000 shs ($3.43M)
Approx. gross sale proceeds
$3.43M
Approx. exercise cost
$604K
Approx. pre-tax spread
$2.83M
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Option to Purchase Common Stock | 10,000 | $12.07 | $121K |
| Exercise | Common Stock | 10,000 | $12.07 | $121K |
| Sale | Common Stock | 2,100 | $68.102 | $143K |
| Sale | Common Stock | 3,350 | $68.88 | $231K |
| Sale | Common Stock | 3,950 | $69.787 | $276K |
| Sale | Common Stock | 600 | $70.812 | $42K |
| Exercise | Option to Purchase Common Stock | 20,000 | $12.07 | $241K |
| Exercise | Common Stock | 20,000 | $12.07 | $241K |
| Sale | Common Stock | 100 | $67.85 | $7K |
| Sale | Common Stock | 1,398 | $70.287 | $98K |
| Sale | Common Stock | 9,802 | $71.37 | $700K |
| Sale | Common Stock | 5,900 | $72.148 | $426K |
| Sale | Common Stock | 2,800 | $73.121 | $205K |
| Exercise | Option to Purchase Common Stock | 20,000 | $12.07 | $241K |
| Exercise | Common Stock | 20,000 | $12.07 | $241K |
| Sale | Common Stock | 9,725 | $64.631 | $629K |
| Sale | Common Stock | 3,575 | $65.458 | $234K |
| Sale | Common Stock | 6,700 | $66.327 | $444K |
Holdings After Transaction:
Option to Purchase Common Stock — 51,923 contracts (Direct);
Common Stock — 767,780 shares (Direct)
Footnotes (13)
- F1. The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on March 21, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2027.
- F2. Represents a weighted average sales price per share. The shares were sold at prices ranging from $64.030 to $65.010. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- F3. Represents a weighted average sales price per share. The shares were sold at prices ranging from $65.030 to $66.010. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- F4. Represents a weighted average sales price per share. The shares were sold at prices ranging from $66.040 to $66.720. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- F5. Represents a weighted average sales price per share. The shares were sold at prices ranging from $69.740 to $70.700. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- F6. Represents a weighted average sales price per share. The shares were sold at prices ranging from $70.800 to $71.795 The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- F7. Represents a weighted average sales price per share. The shares were sold at prices ranging from $71.805 to $72.780. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- F8. Represents a weighted average sales price per share. The shares were sold at prices ranging from $72.810 to $73.770. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- F9. Represents a weighted average sales price per share. The shares were sold at prices ranging from $67.450 to $68.440. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- F10. Represents a weighted average sales price per share. The shares were sold at prices ranging from $68.450 to $69.440. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- F11. Represents a weighted average sales price per share. The shares were sold at prices ranging from $69.450 to $70.050. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- F12. Represents a weighted average sales price per share. The shares were sold at prices ranging from $70.480 to $71.220. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- F13. Grant to Reporting Person of options, exercisable over a 4-year period measured from the date of grant, 25% after 12 months, then 1/48th of the Option Shares per month thereafter. The date of grant was February 22, 2017.
Key Figures
Shares sold: 50,000 shares
Options exercised: 50,000 shares
Option exercise price: $12.07 per share
+3 more
6 metrics
Shares sold
50,000 shares
Total Halozyme common shares sold May 11–13, 2026
Options exercised
50,000 shares
Common stock acquired via option exercises May 11–13, 2026
Option exercise price
$12.07 per share
Exercise price for options converted into common stock
Post-transaction holdings
777,780 shares
Common stock directly held by CEO after transactions
Remaining options
51,923 options
Options to purchase common stock after reported exercises
Sale price example
$73.121 per share
One reported open-market sale price on May 12, 2026
Key Terms
Rule 10b5-1, stock options, weighted average sales price per share, derivative security, +2 more
6 terms
Rule 10b5-1 regulatory
"made pursuant to a written trading plan adopted by the Reporting Person on March 21, 2025 in accordance with Rule 10b5-1"
Rule 10b5-1 is a regulation that allows company insiders to buy or sell their shares at predetermined times, even if they have access to non-public information. It acts like setting a schedule in advance for transactions, helping prevent accusations of unfair trading. This rule provides a way for insiders to plan trades transparently, giving investors confidence that these transactions are not based on hidden information.
stock options financial
"shares that were acquired following exercise of stock options with a ten-year term expiring in February 2027"
Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.
derivative security financial
"transaction_code_description": "Exercise or conversion of derivative security""
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
Option to Purchase Common Stock financial
""security_title": "Option to Purchase Common Stock""
ten-year term financial
"stock options with a ten-year term expiring in February 2027"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did HALO (Halozyme Therapeutics) CEO Helen Torley report in this Form 4?
Helen Torley reported exercising stock options and selling common shares. She exercised 50,000 options at $12.07 and sold 50,000 shares in open-market trades, all under a pre-arranged Rule 10b5-1 trading plan adopted in March 2025.
What stock options did the Halozyme CEO exercise in this filing?
Helen Torley exercised options covering 50,000 shares of Halozyme common stock at an exercise price of $12.07 per share. These options were part of a grant dated February 22, 2017 and had a ten-year term expiring in February 2027.
Does the Halozyme CEO still have stock options after these exercises?
Yes. Following the exercises reported, Helen Torley retains vested options to purchase 51,923 shares of Halozyme common stock. This remaining option balance is shown as the total options following the last derivative transaction in the Form 4 data.
AI-generated analysis. How Rhea-AI works. Not financial advice.
